https://pharmadevicenews.com/innate-pharma-faces-a-crucial-november-update-can-its-adc-pipeline-and-sobi-deal-strengthen-its-position/ PharmaDeviceNews en 2026-10-22T04:04:06+00:00 Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position? AstraZeneca, Innate Pharma, IPH4502, IPH5201, lacutamab, monalizumab, PACIFIC-9, Swedish Orphan Biovitrum, TELLOMAK-3 https://pharmadevicenews.com/wp-content/uploads/2026/10/Innate-Pharma-November-Milestones-e1792641793412.webp https://pharmadevicenews.com/johnson-johnson-advances-surgical-ai-network-with-abu-dhabi-and-polyphonic-platform/ PharmaDeviceNews en 2026-10-22T03:40:26+00:00 Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform Amazon Web Services, Cleveland Clinic Abu Dhabi, Department of Health Abu Dhabi, Hub71, Johnson & Johnson, Johnson & Johnson MedTech, MONARCH, MONARCH QUEST, NVIDIA, Polyphonic https://pharmadevicenews.com/wp-content/uploads/2026/10/AI-Surgery-Arrives-in-Abu-Dhabi-e1792640364255.webp https://pharmadevicenews.com/olorofim-phase-3-results-show-fewer-kidney-complications-in-patients-with-invasive-aspergillosis/ PharmaDeviceNews en 2026-10-21T21:22:37+00:00 Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis AmBisome, European Medicines Agency, F2G Ltd., Ltd., Olorofim, Shionogi & Co., U.S. Food and Drug Administration, University Hospitals Leuven https://pharmadevicenews.com/wp-content/uploads/2026/10/Aspergillosis-research-e1792617639916.webp https://pharmadevicenews.com/roivant-and-priovant-report-62-steroid-free-disease-control-with-brepocitinib-in-uveitis-trials/ PharmaDeviceNews en 2026-10-21T21:06:17+00:00 Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials https://pharmadevicenews.com/wp-content/uploads/2026/10/Ophthalmology-Images-e1792616628827.webp https://pharmadevicenews.com/od-001-ulcerative-colitis-study-shows-clinical-response-in-61-of-higher-dose-patients/ PharmaDeviceNews en 2026-10-21T01:58:32+00:00 OD-001 ulcerative colitis study shows clinical response in 61% of higher-dose patients OD-001, Odyssey Therapeutics, U.S. Food and Drug Administration, United European Gastroenterology https://pharmadevicenews.com/wp-content/uploads/2026/10/Ulcerative-colitis-research-e1792547467193.webp